Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes

References

• Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med. 2003;127(7):834–839.12823037
   PubMed Web of Science ®Google Scholar
• Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312–322. doi:10.1111/jth.1357127868334
   PubMed Web of Science ®Google Scholar
• Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood. 2017;130(10):1181–1188. doi:10.1182/blood-2017-04-63643128768626
   PubMed Web of Science ®Google Scholar
• Elverdi T, Eskazan AE. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura. Drug Des Devel Ther. 2019;13:1251–1258. doi:10.2147/DDDT.S134470
   PubMed Web of Science ®Google Scholar
• Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group. N Engl J Med. 1991;325(6):393–397. doi:10.1056/NEJM1991080832506042062330
   PubMed Web of Science ®Google Scholar
• Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura published correction appears in blood. Blood. 2015;125(25):3860–3867. doi:10.1182/blood-2014-11-55158025784681
   PubMed Web of Science ®Google Scholar
• Roose E, Schelpe AS, Tellier E, et al. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood. 2020;136(3):353–361.32356859
   PubMed Web of Science ®Google Scholar
• Masias C, Cataland SR. The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis. Blood. 2018;132(9):903–910. doi:10.1182/blood-2018-02-79153330006329
   PubMed Web of Science ®Google Scholar
• Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Pathol Soc. 1924;24:21–24.
   Google Scholar
• Nokes T, George JN, Vesely SK, Awab A. Pulmonary involvement in patients with thrombotic thrombocytopenic purpura. Eur J Haematol. 2014;92(2):156–163. doi:10.1111/ejh.1222224164539
   PubMed Web of Science ®Google Scholar
• Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45(2):139–160. doi:10.1097/00005792-196603000-00003
   Web of Science ®Google Scholar
• Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157–e164. doi:10.1016/S2352-3026(17)30026-128259520
   PubMed Web of Science ®Google Scholar
• Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836–2846. doi:10.1182/blood-2016-10-70985728416507
   PubMed Web of Science ®Google Scholar
• Sadler JE. What’s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2015;2015(1):631–636.26637781
   PubMed Web of Science ®Google Scholar
• Chiasakul T, Cuker A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematology Am Soc Hematol Educ Program. 2018;2018(1):530–538. doi:10.1182/asheducation-2018.1.53030504354
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Salihoglu A. Treatment and outcome of primary and secondary thrombotic microangiopathies. Am J Nephrol. 2015;41(6):427–428. doi:10.1159/00043700226183157
   PubMed Web of Science ®Google Scholar
• Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol. 2014;164(6):759–766. doi:10.1111/bjh.1271824387053
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98(9):2730–2735. doi:10.1182/blood.V98.9.273011675345
   PubMed Web of Science ®Google Scholar
• Shelat SG, Smith P, Ai J, Zheng XL. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost. 2006;4(8):1707–1717. doi:10.1111/j.1538-7836.2006.02025.x16879212
   PubMed Web of Science ®Google Scholar
• Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106(4):1262–1267. doi:10.1182/blood-2004-11-449015890682
   PubMed Web of Science ®Google Scholar
• Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500–1662. doi:10.1182/blood-2009-09-24379020032506
   PubMed Web of Science ®Google Scholar
• Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103(11):4043–4049. doi:10.1182/blood-2003-11-403514982878
   PubMed Web of Science ®Google Scholar
• Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med. 2014;5:15–23.24523598
   PubMedGoogle Scholar
• McClain RS, Terrell DR, Vesely SK, George JN. Plasma exchange complications in patients treated for thrombotic thrombocytopenia purpura-hemolytic uremic syndrome: 2011 to 2014. Transfusion. 2014;54(12):3257–3259. doi:10.1111/trf.1291725496391
   PubMed Web of Science ®Google Scholar
• Som S, Deford CC, Kaiser ML, et al. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion. 2012;52(12):2525. doi:10.1111/j.1537-2995.2012.03646.x22501034
   PubMed Web of Science ®Google Scholar
• George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010 published correction appears in blood. Blood. 2010;116(20):4060–4069. doi:10.1182/blood-2010-07-27144520686117
   PubMed Web of Science ®Google Scholar
• Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol. 2011;86(9):743–751. doi:10.1002/ajh.2209121850657
   PubMed Web of Science ®Google Scholar
• George JN. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology (Williston Park). 2011;25(10):908–914.22010388
   PubMed Web of Science ®Google Scholar
• Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher. 2019;34(3):171–354.31180581
   PubMed Web of Science ®Google Scholar
• Nguyen L, Li X, Duvall D, Terrell DR, Vesely SK, George JN. Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma registry, 1989 through 2006. Transfusion. 2008;48(2):349–357.18028271
   PubMed Web of Science ®Google Scholar
• Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136(3):451–461. doi:10.1111/j.1365-2141.2006.06448.x17233847
   PubMed Web of Science ®Google Scholar
• Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French thrombotic microangiopathies reference center. Crit Care Med. 2012;40(1):104–111. doi:10.1097/CCM.0b013e31822e9d6621926591
   PubMed Web of Science ®Google Scholar
• Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015;125(10):1526–1531. doi:10.1182/blood-2014-10-55921125573992
   PubMed Web of Science ®Google Scholar
• Jestin M, Benhamou Y, Schelpe AS, et al. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2018;132(20):2143–2153. doi:10.1182/blood-2018-04-84009030201758
   PubMed Web of Science ®Google Scholar
• Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103705s5299lbl.pdf. Accessed 220, 2020.
   Google Scholar
• McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(6):1201–1208. doi:10.1111/j.1538-7836.2010.03818.x20175870
   PubMed Web of Science ®Google Scholar
• Duggan S. Caplacizumab: first global approval published correction appears in drugs. Drugs. 2018;78(15):1639–1642. doi:10.1007/s40265-018-0989-030298461
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511–522. doi:10.1056/NEJMoa150553326863353
   PubMed Web of Science ®Google Scholar
• Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335–346. doi:10.1056/NEJMoa180631130625070
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Eskazan AE, Unsal A, et al. Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature. Transfusion. 2013;53(7):1586–1593. doi:10.1111/j.1537-2995.2012.03944.x23121663
   PubMed Web of Science ®Google Scholar
• Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med. 2003;138(2):105–108. doi:10.7326/0003-4819-138-2-200301210-0001112529092
   PubMed Web of Science ®Google Scholar
• Ahmad HN, Thomas-Dewing RR, Hunt BJ. Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura. Eur J Haematol. 2007;78(5):449–452. doi:10.1111/j.1600-0609.2007.00832.x17331134
   PubMed Web of Science ®Google Scholar
• Öngören S, Salihoğlu A, Apaydın T, et al. Vincristine as an adjunct to therapeutic plasma exchange for thrombotic thrombocytopenic purpura: a single-institution experience. Balk Med J. 2018;35(6):417–421.
   Web of Science ®Google Scholar
• Eskazan AE. Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura. Ann Hematol. 2016;95(11):1751–1756. doi:10.1007/s00277-016-2804-x27590601
   PubMed Web of Science ®Google Scholar
• Rottenstreich A, Hochberg-Klein S, Rund D, Kalish Y. The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura. J Thromb Thrombolysis. 2016;41(4):678–683. doi:10.1007/s11239-015-1259-626245827
   PubMed Web of Science ®Google Scholar
• Kappers-Klunne MC, Wijermans P, Fijnheer R, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol. 2005;130(5):768–776. doi:10.1111/j.1365-2141.2005.05681.x16115135
   PubMed Web of Science ®Google Scholar
• Riviere E, Saint-Léger M, James C, et al. Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count. Transfusion. 2015;55(7):1798–1802. doi:10.1111/trf.1304125702952
   PubMed Web of Science ®Google Scholar
• Alias H, Yong WL, Muttlib FAA, et al. Acquired thrombotic thrombocytopenia purpura associated with severe ADAMTS13 deficiency in a 3-year-old boy: a case report and review of the literature. J Med Case Rep. 2018;12(1):276. doi:10.1186/s13256-018-1806-930223886
   PubMedGoogle Scholar
• Roose E, Joly BS. Current and future perspectives on ADAMTS13 and Thrombotic thrombocytopenic purpura. Hamostaseologie. 2020;40(3):322–336. doi:10.1055/a-1171-047332726827
   PubMed Web of Science ®Google Scholar
• Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood. 2016;128(17):2175–2178. doi:10.1182/blood-2016-06-72416127625362
   PubMed Web of Science ®Google Scholar
• Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol. 2008;141(5):651–658. doi:10.1111/j.1365-2141.2008.07107.x18397340
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008;93(2):232–239. doi:10.3324/haematol.1173918223285
   PubMed Web of Science ®Google Scholar
• Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti- ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood. 2007;109(7):2815–2822. doi:10.1182/blood-2006-02-00606417164349
   PubMed Web of Science ®Google Scholar
• Schieppati F, Russo L, Marchetti M, et al. Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: a multi-institutional study. Am J Hematol. 2020;1–56.
   Web of Science ®Google Scholar
• Sui J, Cao W, Halkidis K, et al. Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura. Blood Adv. 2019;3(24):4177–4186. doi:10.1182/bloodadvances.201900093931856267
   PubMed Web of Science ®Google Scholar
• Pillai VG, Bao J, Zander CB, et al. Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP. Blood. 2016;128(01):110–119. doi:10.1182/blood-2015-12-68874727207796
   PubMed Web of Science ®Google Scholar
• Westwood JP, Thomas M, Alwan F, et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Adv. 2017;1(15):1159–1166. doi:10.1182/bloodadvances.201700826829296757
   PubMed Web of Science ®Google Scholar
• George JN. TTP: long-term outcomes following recovery. Hematology Am Soc Hematol Educ Program. 2018;2018(1):548–552. doi:10.1182/asheducation-2018.1.54830504356
   PubMed Web of Science ®Google Scholar
• Vesely SK. Life after acquired thrombotic thrombocytopenic purpura: morbidity, mortality, and risks during pregnancy. J Thromb Haemost. 2015;13(Suppl 1):S216–S222. doi:10.1111/jth.1295326149027
   PubMed Web of Science ®Google Scholar
• Prevel R, Roubaud-Baudron C, Gourlain S, et al. For the French reference center for thrombotic microangiopathies, immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival. Blood. 2019;134(24):2209–2217. doi:10.1182/blood.201900074831530564
   PubMed Web of Science ®Google Scholar